CEVI logo

CellaVision AB (publ) Stock Price

OM:CEVI Community·SEK 2.9b Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author

CEVI Share Price Performance

SEK 120.40
-75.20 (-38.45%)
SEK 140.00
Fair Value
SEK 120.40
-75.20 (-38.45%)
14.0% undervalued intrinsic discount
SEK 140.00
Fair Value
Price SEK 120.40
AnalystLowTarget SEK 140.00
AnalystConsensusTarget SEK 179.00

CEVI Community Narratives

·
Fair Value SEK 140 14.0% undervalued intrinsic discount

Tender Risks In Digital Hematology Will Eventually Be Offset By New Applications

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value SEK 179 32.7% undervalued intrinsic discount

Upcoming Bone Marrow Launch And APAC Expansion Will Unlock Markets

0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
SEK 140
14.0% undervalued intrinsic discount
Revenue
8.58% p.a.
Profit Margin
19.55%
Future PE
21.76x
Price in 2029
SEK 166.83

Trending Discussion

Updated Narratives

CEVI logo

CEVI: Bone Marrow Launch And Dividend Will Support Future Upside

Fair Value: SEK 179 32.7% undervalued intrinsic discount
13 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CEVI logo

Tender Risks In Digital Hematology Will Eventually Be Offset By New Applications

Fair Value: SEK 140 14.0% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with flawless balance sheet and pays a dividend.

1 Risk
4 Rewards

CellaVision AB (publ) Key Details

SEK 730.6m

Revenue

SEK 233.9m

Cost of Revenue

SEK 496.7m

Gross Profit

SEK 362.6m

Other Expenses

SEK 134.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 17, 2026
5.62
67.98%
18.35%
2.5%
View Full Analysis

About CEVI

Founded
1994
Employees
241
CEO
Simon Ostergaard
WebsiteView website
www.cellavision.com

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company’s CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.

Recent CEVI News & Updates

Narrative Update Apr 30

CEVI: Bone Marrow Launch And Dividend Will Support Future Upside

Analysts have trimmed their CellaVision price target from SEK225 to SEK179. This reflects updated assumptions for slightly lower revenue growth, profit margins and future P/E, alongside a higher discount rate in their models.
New Narrative Apr 29

Tender Risks In Digital Hematology Will Eventually Be Offset By New Applications

Catalysts About CellaVision CellaVision develops digital microscopy and software solutions for hematology laboratories worldwide. What are the underlying business or industry changes driving this perspective?

Recent updates

No updates